Trial Profile

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zumilokibart (Primary) ; Lebrikizumab
Indications Atopic dermatitis
Focus Proof of concept; Therapeutic Use
Acronyms APEX
Sponsors Apogee Therapeutics

Most Recent Events

10 Aug 2026 Results presented in the Apogee Therapeutics media release.
27 May 2026 Results of positive 16-week data from Part B induction dose optimization from this clinical trial presented in an Apogee Therapeutics media release.
27 May 2026 According to an Apogee Therapeutics media release, company will hold a live webcast to discuss the Blackstone transaction and the results of the APEX Phase 2 Part B trial today at 8:00 a.m. ET.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com